These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

735 related items for PubMed ID: 9406695

  • 1. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
    Behr TM, Gratz S, Markus PM, Dunn RM, Hüfner M, Schauer A, Fischer M, Munz DL, Becker H, Becker W.
    Cancer; 1997 Dec 15; 80(12 Suppl):2436-57. PubMed ID: 9406695
    [Abstract] [Full Text] [Related]

  • 2. Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen.
    Juweid M, Sharkey RM, Behr T, Swayne LC, Rubin AD, Herskovic T, Hanley D, Markowitz A, Dunn R, Siegel J, Kamal T, Goldenberg DM.
    J Clin Oncol; 1996 Apr 15; 14(4):1209-17. PubMed ID: 8648376
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.
    Mucha SA, Kunert-Radek J, Pomorski L.
    Endokrynol Pol; 2006 Apr 15; 57(4):452-5. PubMed ID: 17006852
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Somatostatin and somatostatin analogues in medullary thyroid carcinoma.
    O'Byrne KJ, O'Hare N, Sweeney E, Freyne PJ, Cullen MJ.
    Nucl Med Commun; 1996 Sep 15; 17(9):810-6. PubMed ID: 8895910
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
    Eising EG, Farahati J, Bier D, Knust EJ, Reiners C.
    Nuklearmedizin; 1995 Feb 15; 34(1):1-7. PubMed ID: 7724358
    [Abstract] [Full Text] [Related]

  • 9. Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma.
    Bernà L, Chico A, Matías-Guiu X, Mato E, Catafau A, Alonso C, Mora J, Mauricio D, Rodríguez-Espinosa J, Marí C, Flotats A, Martín JC, Estorch M, Carrió I.
    Eur J Nucl Med; 1998 Nov 15; 25(11):1482-8. PubMed ID: 9799343
    [Abstract] [Full Text] [Related]

  • 10. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings.
    Adams S, Baum RP, Hertel A, Schumm-Draeger PM, Usadel KH, Hör G.
    Eur J Nucl Med; 1998 Sep 15; 25(9):1277-83. PubMed ID: 9724377
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with 131I-labeled monoclonal antibodies to carcinoembryonic antigen.
    Juweid M, Sharkey RM, Behr T, Swayne LC, Rubin AD, Hanley D, Herskovic T, Markowitz A, Siegel J, Goldenberg DM.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5946s-5951s. PubMed ID: 7493375
    [Abstract] [Full Text] [Related]

  • 14. Improved selection of patients for reoperation for medullary thyroid cancer by imaging with radiolabeled anticarcinoembryonic antigen antibodies.
    Juweid M, Sharkey RM, Swayne LC, Goldenberg DM.
    Surgery; 1997 Dec 01; 122(6):1156-65. PubMed ID: 9426433
    [Abstract] [Full Text] [Related]

  • 15. Functional nuclear medicine imaging of medullary thyroid cancer.
    Bozkurt MF, Uğur O, Banti E, Grassetto G, Rubello D.
    Nucl Med Commun; 2008 Nov 01; 29(11):934-42. PubMed ID: 18836370
    [Abstract] [Full Text] [Related]

  • 16. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.
    Barbet J, Peltier P, Bardet S, Vuillez JP, Bachelot I, Denet S, Olivier P, Leccia F, Corcuff B, Huglo D, Proye C, Rouvier E, Meyer P, Chatal JF.
    J Nucl Med; 1998 Jul 01; 39(7):1172-8. PubMed ID: 9669389
    [Abstract] [Full Text] [Related]

  • 17. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.
    Behr TM, Béhé MP.
    Semin Nucl Med; 2002 Apr 01; 32(2):97-109. PubMed ID: 11965605
    [Abstract] [Full Text] [Related]

  • 18. Somatostatin receptor scintigraphy for early detection of regional and distant metastases of medullary carcinoma of the thyroid.
    Krausz Y, Rosler A, Guttmann H, Ish-Shalom S, Shibley N, Chisin R, Glaser B.
    Clin Nucl Med; 1999 Apr 01; 24(4):256-60. PubMed ID: 10466522
    [Abstract] [Full Text] [Related]

  • 19. 68Ga-DOTANOC and 18F-FDG PET/CT in metastatic medullary thyroid carcinoma: novel correlations with tumoral biomarkers.
    Souteiro P, Gouveia P, Ferreira G, Belo S, Costa C, Carvalho D, Duarte H, Sampaio IL.
    Endocrine; 2019 May 01; 64(2):322-329. PubMed ID: 30684230
    [Abstract] [Full Text] [Related]

  • 20. Combined use of 111In-DTPA-D-Phe-1-octreotide (OCT) and 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC).
    Kurtaran A, Leimer M, Kaserer K, Yang Q, Angelberger P, Niederle B, Virgolini I.
    Nucl Med Biol; 1996 May 01; 23(4):503-7. PubMed ID: 8832707
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.